Merck extends pact with NK cell specialists at Artiva; Regeneron-allied biotech pencils in $15M IPO
More than a year into its discovery pact with the NK cell specialists at Artiva, Merck is apparently happy with what it’s seen so far …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
